# OnCo record cosibelimab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/cosibelimab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "cosibelimab" ;
  schema:name "Cosibelimab"@en ;
  schema:description "Cosibelimab is a PD-L1 antibody approved in December 2024 for advanced cutaneous squamous cell carcinoma, offering a third immunotherapy choice."@en ;
  schema:url <https://onco.cc/drugs/cosibelimab/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Cosibelimab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q131612073> ;
  schema:citation <https://doi.org/10.1136/jitc-2023-007637>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06bdadd5-d2db-406f-a3f8-de47f48a52e3> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Anti-PD-L1 monoclonal antibody (IgG1, ADCC-competent)" ;
  schema:alternateName "Unloxcyt" ;
  onco:approval "US 2024: Metastatic or locally advanced cutaneous SCC not curable by surgery or radiation" ;
  onco:cancers <https://onco.cc/cancers/cutaneous-scc/>, <https://onco.cc/cancers/advanced-cutaneous-scc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pdl1/> ;
  onco:companies <https://onco.cc/companies/checkpoint-therapeutics/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:trials <https://onco.cc/trials/ck-301-101/>, <https://onco.cc/trials/nct04786964/> .